Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting-Reference-Cited by-同舟云学术

Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting

Published:2012-08-10 Issue:12 Volume:67 Page:2943-2948
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:Journal of Antimicrobial Chemotherapy

Author:

Maiga A. I.,Fofana D. B.,Cisse M.,Diallo F.,Maiga M. Y.,Traore H. A.,Maiga I. A.,Sylla A.,Fofana D.,Taiwo B.,Murphy R.,Katlama C.,Tounkara A.,Calvez V.,Marcelin A.-G.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/67/12/2943/2329117/dks310.pdf

Reference21 articles.

1. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali

2. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen

3. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa

4. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring

5. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019–2021;International Journal of Antimicrobial Agents;2024-02

2. Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens;Viruses;2023-08-02

3. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance;AIDS Research and Therapy;2023-01-05

4. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya;Medicine;2021-10-08

5. Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa;BMC Infectious Diseases;2021-02-25